CAMBRIDGE, Mass., March 28, 2017 /PRNewswire/ -- Spero Therapeutics, LLC, a biopharmaceutical company founded to developnovel therapies to treat bacterial infections, announced today that Ankit Mahadevia, President and CEO, will present a company overview at the 16th Annual Needham Healthcare Conference on Tuesday,
About Spero Spero Therapeutics is a global multi-asset clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to developing a novel and highly differentiated pipeline of antibacterials focused on unmet needs of patients with drug resistant bacterial infections. Spero Therapeutics is advancing two lead programs in parallel, SPR741 and SPR994. SPR741, also called Potentiator, is a platform approach to combination therapy to treat serious and life-threatening multi-drug resistant gram negative infections, such as Enterobacteriaceae and Acinetobacter baumanii, including carbapenem resistant strains. SPR741 increases the spectrum and potency of more than two dozen classes of gram positive antibiotics to include activity against multidrug resistant gram negative infections when used in combination. SPR994 is a novel oral agent that has demonstrated potent invitro activity against a wide variety of gram-negative bacteria, including extended spectrum beta lactamases (ESBLs), and gram-positive bacteria. Spero Therapeutics also has a robust preclinical pipeline including SPR720, which is a preclinical oral asset for nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic fatal infection. In addition, Spero Therapeutics has a variety of other discovery antimicrobials focused on drug-resistant infections.
For more information, please visit https://sperotherapeutics.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spero-therapeutics-to-present-at-16th-annual-needham-healthcare-conference-300428853.html
SOURCE Spero Therapeutics
Subscribe to our Free Newsletters!